Evidence map›Paper›PMID 41741724›Full record

ArticleEMBO reports2026

Mechanical force regulates the inhibitory function of PD-1.

Hui Chen, Yong Zhang, Lei Cui, Juan Fan, Huaying Zhu, Songfang Wu, Hang Zhou, Yanruo Zhang, Guangtao Song, Ning Jiang and 4 more

Abstract read
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hui Chen *State Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. cdchenhui@ibp.ac.cn.ORCID 0000-0003-1642-621X
Yong Zhang *State Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Lei Cui *State Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Juan FanCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the MOE Frontier Science Center for Brain Science & Brain-machine Integration, State Key Laboratory for Modern Optical Instrumentation Key Laboratory for Biomedical Engineering of the Ministry of Education, College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang, China.
Huaying ZhuCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the MOE Frontier Science Center for Brain Science & Brain-machine Integration, State Key Laboratory for Modern Optical Instrumentation Key Laboratory for Biomedical Engineering of the Ministry of Education, College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang, China.ORCID 0009-0005-0115-6677
Songfang WuState Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Hang ZhouState Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Yanruo ZhangState Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Guangtao SongState Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Ning JiangDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Mingzhao ZhuState Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.ORCID 0000-0003-2001-2669
Changjie LouDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150001, Heilongjiang, China. 601245@hrbmu.edu.cn.ORCID 0009-0002-9925-3667
Wei ChenCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the MOE Frontier Science Center for Brain Science & Brain-machine Integration, State Key Laboratory for Modern Optical Instrumentation Key Laboratory for Biomedical Engineering of the Ministry of Education, College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang, China. jackweichen@zju.edu.cn.ORCID 0000-0001-5366-7253
Jizhong LouState Key Laboratory of Epigenetic Regulation and Intervention, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. jlou@ibp.ac.cn.ORCID 0000-0003-4031-6125

Funding

Beijing Medical Award Foundation ( ) YZTZ-2022-0080-0015| Henan Provincial Science and Technology Research Project ( ) 242102310348MOST | National Natural Science Foundation of China (NSFC) 11672317MOST | National Natural Science Foundation of China (NSFC) 12172371MOST | National Natural Science Foundation of China (NSFC) 32090044MOST | National Natural Science Foundation of China (NSFC) 32200549MOST | National Natural Science Foundation of China (NSFC) 32301035MOST | National Natural Science Foundation of China (NSFC) T2394511MOST | National Natural Science Foundation of China (NSFC) T2394512Strategic Priority Research Program of the Chinese Academy of Sciences XDB37020102
6 · The paper itself

Abstract

The immune checkpoint molecule, programmed cell death 1 (PD-1), critically regulates T-cell activation upon binding PD-L1 or PD-L2, making it a key target in cancer immunotherapy. Although extensively studied, the molecular mechanism of the inhibitory function of PD-1 remains incompletely understood. Using the biomembrane force probe (BFP), we measure catch-slip bond behavior between PD-1 and PD-L1/PD-L2 under force. Steered molecular dynamics (SMD) simulation reveals a force-induced bound state distinct from the force-free state observed in solved complex structures. Disrupting interactions that stabilize either state weakens the catch bond, and diminishes the inhibitory function of PD-1. Interestingly, soluble forms of PD-L1/PD-L2 compete with their surface-bound counterparts and attenuate PD-1-mediated T-cell inhibition, suggesting that soluble PD-1 ligands could potentially serve as anti-PD-1 drugs. Tumor growth studies using a gain of function mutant based on the catch-bond mechanism confirm the anti-cancer activity of soluble PD-L1. Our findings highlight that mechanical force governs the inhibitory function of PD-1 and suggest that PD-1 acts as a mechanical sensor in T-cell suppression. Thus, mechanical regulation should be considered when designing PD-1 blocking therapies.

Indexed as

B7-H1 AntigenProgrammed Cell Death 1 ReceptorAnimalsHumansMolecular Dynamics SimulationProgrammed Cell Death 1 Ligand 2 ProteinProtein BindingT-LymphocytesB7-H1 AntigenCD274 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 Ligand 2 ProteinProgrammed Cell Death 1 ReceptorImmunological SynapseImmunotherapyMechanical ForcePD-1T Cells

Identifiers

PMID41741724
PMCPMC13076993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.